[A20-16] Niraparib (ovarian cancer) - Addendum to Commission A19-88

Last updated 02.04.2020

Project no.:
A20-16

Commission:
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Maintenance treatment of platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with complete or partial response to platinum-based chemotherapy

Result of dossier assessment:

The data subsequently submitted have changed the conclusion of the assessment: now hint of lesser benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2020-04-02 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.